Market cap of Maravai LifeSciences Holdings Inc. [MRVI] reaches 3.51B – now what?

Maravai LifeSciences Holdings Inc. [NASDAQ: MRVI] stock went on an upward path that rose over 4.64% on Thursday, amounting to a one-week price decrease of less than -7.64%. The company report on December 1, 2022 that Maravai LifeSciences Announces Updated CEO Leadership Transition Plans.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Maravai announces plans for William “Trey” Martin, III to serve as President of its Biologics Safety Testing Segment and its expectation that he will then assume the role of Maravai’s CEO in July 2023.

Carl Hull to continue to serve as Executive Chairman and Interim CEO.

Over the last 12 months, MRVI stock dropped by -69.26%. The one-year Maravai LifeSciences Holdings Inc. stock forecast points to a potential upside of 44.07. The average equity rating for MRVI stock is currently 1.70, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $3.51 billion, with 131.54 million shares outstanding and 109.24 million shares in the current float. Compared to the average trading volume of 2.11M shares, MRVI stock reached a trading volume of 2399941 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Maravai LifeSciences Holdings Inc. [MRVI]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRVI shares is $23.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRVI stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

RBC Capital Mkts have made an estimate for Maravai LifeSciences Holdings Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 07, 2022. While these analysts kept the previous recommendation, BofA Securities dropped their target price from $32 to $17. The new note on the price target was released on November 03, 2022, representing the official price target for Maravai LifeSciences Holdings Inc. stock. Previously, the target price had yet another raise to $34, while Credit Suisse analysts kept a Outperform rating on MRVI stock.

The Average True Range (ATR) for Maravai LifeSciences Holdings Inc. is set at 0.89, with the Price to Sales ratio for MRVI stock in the period of the last 12 months amounting to 3.88. The Price to Book ratio for the last quarter was 3.47, with the Price to Cash per share for the same quarter was set at 2.34. Price to Free Cash Flow for MRVI in the course of the last twelve months was 6.00 with Quick ratio for the last quarter at 6.70.

MRVI Stock Performance Analysis:

Maravai LifeSciences Holdings Inc. [MRVI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.64. With this latest performance, MRVI shares dropped by -6.67% in over the last four-week period, additionally sinking by -54.26% over the last 6 months – not to mention a drop of -69.26% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRVI stock in for the last two-week period is set at 38.25, with the RSI for the last a single of trading hit 39.92, and the three-weeks RSI is set at 37.41 for Maravai LifeSciences Holdings Inc. [MRVI]. The present Moving Average for the last 50 days of trading for this stock 16.60, while it was recorded at 13.15 for the last single week of trading, and 26.66 for the last 200 days.

Insight into Maravai LifeSciences Holdings Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Maravai LifeSciences Holdings Inc. [MRVI] shares currently have an operating margin of +68.18 and a Gross Margin at +81.67. Maravai LifeSciences Holdings Inc.’s Net Margin is presently recorded at +22.78.

Return on Equity for this stock inclined to 90.12, with Return on Assets sitting at 11.42.

Maravai LifeSciences Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.70 and a Current Ratio set at 7.20.

Maravai LifeSciences Holdings Inc. [MRVI] Insider Position Details

There are presently around $1,731 million, or 97.55% of MRVI stock, in the hands of institutional investors. The top three institutional holders of MRVI stocks are: GTCR LLC with ownership of 21,681,033, which is approximately 0% of the company’s market cap and around 0.40% of the total institutional ownership; SELECT EQUITY GROUP, L.P., holding 16,450,838 shares of the stock with an approximate value of $218.8 million in MRVI stocks shares; and MASSACHUSETTS FINANCIAL SERVICES CO /MA/, currently with $188.21 million in MRVI stock with ownership of nearly 11.502% of the company’s market capitalization.

Positions in Maravai LifeSciences Holdings Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 105 institutional holders increased their position in Maravai LifeSciences Holdings Inc. [NASDAQ:MRVI] by around 16,245,268 shares. Additionally, 122 investors decreased positions by around 17,124,218 shares, while 25 investors held positions by with 96,799,236 shares. The mentioned changes placed institutional holdings at 130,168,722 shares, according to the latest SEC report filing. MRVI stock had 34 new institutional investments in for a total of 4,242,768 shares, while 46 institutional investors sold positions of 5,182,662 shares during the same period.


Please enter your comment!
Please enter your name here